

# Ashwin Ananthakrishnan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6910490/publications.pdf>

Version: 2024-02-01

294  
papers

25,611  
citations

13332

70  
h-index

9346

148  
g-index

320  
all docs

320  
docs citations

320  
times ranked

32059  
citing authors

#	ARTICLE	IF	CITATIONS
1	Vedolizumab or Tumor Necrosis Factor Antagonist Use and Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease With Prior Malignancy: A Retrospective Cohort Study. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 88-95.	2.4	23
2	Dietary Gluten Intake Is Not Associated With Risk of Inflammatory Bowel Disease in US Adults Without Celiac Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 303-313.e6.	2.4	6
3	Inflammatory Bowel Disease Patients Who Respond to Treatment with Anti-tumor Necrosis Factor Agents Demonstrate Improvement in Pre-treatment Frailty. <i>Digestive Diseases and Sciences</i> , 2022, 67, 622-628.	1.1	19
4	Yield and Predictors of Surveillance Colonoscopies in Older Adults With Long-standing Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e1353-e1364.	2.4	2
5	Ultra-processed Foods and Risk of Crohn's Disease and Ulcerative Colitis: A Prospective Cohort Study. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e1323-e1337.	2.4	60
6	Vedolizumab Is Associated With a Lower Risk of Serious Infections Than Anti-Tumor Necrosis Factor Agents in Older Adults. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1299-1305.e5.	2.4	21
7	Plasma concentrations of perfluoroalkyl substances and risk of inflammatory bowel diseases in women: A nested case control analysis in the Nurses' Health Study cohorts. <i>Environmental Research</i> , 2022, 207, 112222.	3.7	9
8	Risk of Infections With Ustekinumab and Tofacitinib Compared to Tumor Necrosis Factor Inhibitors in Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2366-2372.e6.	2.4	14
9	Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 254-261.	3.7	18
10	Risk Factors for Incident Inflammatory Bowel Disease According to Disease Phenotype. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2347-2357.e14.	2.4	4
11	Fecal Calprotectin Is a Predictor of Need for Rescue Therapy in Hospitalized Severe Colitis. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 1833-1837.	0.9	5
12	Comparative Risk of Thrombotic and Cardiovascular Events with Tofacitinib and Anti-TNF Agents in Patients with Inflammatory Bowel Diseases. <i>Digestive Diseases and Sciences</i> , 2022, 67, 5206-5212.	1.1	9
13	A United States expert consensus to standardise definitions, follow-up, and treatment targets for extra-intestinal manifestations in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1179-1191.	1.9	7
14	Alcohol consumption and risk of inflammatory bowel disease among three prospective US cohorts. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 225-233.	1.9	9
15	Sugars and Gastrointestinal Health. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1912-1924.e7.	2.4	15
16	Recommendations on the appropriate management of steroids and discharge planning during and after hospital admission for moderate-severe ulcerative colitis: results of a RAND appropriateness panel. <i>American Journal of Gastroenterology</i> , 2022, Publish Ahead of Print, .	0.2	3
17	Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases: an International Organization for Study of Inflammatory Bowel Diseases consensus. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 666-678.	3.7	31
18	Issue Highlights. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1195-1196.	2.4	0

#	ARTICLE	IF	CITATIONS
19	E-cigarette Use and Disease Outcomes in Inflammatory Bowel Diseases: A Case-Control Study. <i>Digestive Diseases and Sciences</i> , 2022, , .	1.1	1
20	Infliximab Trough Levels Are Not Predictive of Relapse in Patients with IBD in Endoscopic Remission: A Multicenter Cohort Study. <i>Digestive Diseases and Sciences</i> , 2021, 66, 3548-3554.	1.1	8
21	Treat to Target: The Role of Histologic Healing in Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1800-1813.e4.	2.4	70
22	Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1366-1376.e2.	2.4	55
23	Frequency of Opioid Prescription at Emergency Department Discharge in Patients with Inflammatory Bowel Disease: A Nationwide Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2064-2071.e1.	2.4	8
24	Robust and efficient semi-supervised estimation of average treatment effects with application to electronic health records data. <i>Biometrics</i> , 2021, 77, 413-423.	0.8	4
25	Healthy Lifestyle Is Associated With Reduced Mortality in Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 87-95.e4.	2.4	47
26	Alterations in Fecal Microbiomes and Serum Metabolomes of Fatigued Patients With Quiescent Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 519-527.e5.	2.4	31
27	Phenotype and Natural History of Inflammatory Bowel Disease in Patients With Concomitant Eosinophilic Esophagitis. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 469-475.	0.9	8
28	Characteristics and Long-Term Outcomes of Pregnancy-Onset Inflammatory Bowel Disease: A Case-Control Study. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 476-481.	0.9	3
29	A Phenome-Wide Analysis of Healthcare Costs Associated with Inflammatory Bowel Diseases. <i>Digestive Diseases and Sciences</i> , 2021, 66, 760-767.	1.1	12
30	Ileal or Colonic Histologic Activity Is Not Associated With Clinical Relapse in Patients With Crohn's Disease in Endoscopic Remission. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1226-1233.e1.	2.4	12
31	Safety and Efficacy of Tumor Necrosis Factor Antagonists in Older Patients With Ulcerative Colitis: Patient-Level Pooled Analysis of Data From Randomized Trials. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 939-946.e4.	2.4	25
32	AGA Clinical Practice Update on Management of Inflammatory Bowel Disease in Elderly Patients: Expert Review. <i>Gastroenterology</i> , 2021, 160, 445-451.	0.6	33
33	Immunosuppressive Therapy and Risk of COVID-19 Infection in Patients With Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 155-161.	0.9	48
34	Yield of Random Biopsies During Colonoscopies in Inflammatory Bowel Disease Patients Undergoing Dysplasia Surveillance. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 779-786.	0.9	26
35	It Is All in the Fine Print: A Call for a Histopathology Checklist for IBD. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 446-447.	2.4	1
36	Diet in Treatment of Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 425-435.e3.	2.4	63

#	ARTICLE	IF	CITATIONS
37	Frailty in inflammatory bowel diseases: an emerging concept. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110254.	1.4	22
38	Economic burden and cost-effectiveness of therapies for <i>Clostridioides difficile</i> infection: a narrative review. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110186.	1.4	30
39	Increasing Prevalence of Frailty and Its Association with Readmission and Mortality Among Hospitalized Patients with IBD. <i>Digestive Diseases and Sciences</i> , 2021, 66, 4178-4190.	1.1	38
40	IBD risk prediction using multi-ethnic polygenic risk scores. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 217-218.	8.2	6
41	Two Strikes but Not Out: Deep Remission of Ulcerative Colitis with Ustekinumab After Primary Non-response to Infliximab and Vedolizumab. <i>Digestive Diseases and Sciences</i> , 2021, 66, 733-737.	1.1	1
42	Time to Negative SARS-CoV-2 PCR Should Not Delay Care Among Patients With Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 590-592.	0.9	0
43	Nutrition in the Management of Inflammatory Bowel Diseases. <i>Gastroenterology Clinics of North America</i> , 2021, 50, 151-167.	1.0	6
44	Systematic Review of Inclusion and Analysis of Older Adults in Randomized Controlled Trials of Medications Used to Treat Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1541-1543.	0.9	21
45	Therapeutic Drug Monitoring of Non-Anti-Tumor Necrosis Factor Biologics. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1108-1110.	2.4	6
46	High Anti-Infliximab Antibody Titers Do Not Impact Response to Subsequent Adalimumab Treatment in Inflammatory Bowel Diseases. <i>Digestive Diseases and Sciences</i> , 2021, , 1.	1.1	3
47	Plant-Based Diet Quality and Risk of Crohn's Disease and Ulcerative Colitis in US Women. <i>Current Developments in Nutrition</i> , 2021, 5, 462.	0.1	1
48	Multi-omics reveal microbial determinants impacting responses to biologic therapies in inflammatory bowel disease. <i>Cell Host and Microbe</i> , 2021, 29, 1294-1304.e4.	5.1	85
49	The role of precision nutrition in the modulation of microbial composition and function in people with inflammatory bowel disease. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 754-769.	3.7	27
50	Efficacy and safety of fecal transplantation versus targeted therapies in ulcerative colitis: network meta-analysis. <i>Future Microbiology</i> , 2021, 16, 1215-1227.	1.0	9
51	Immune-mediated diseases and risk of Crohn's disease or ulcerative colitis: a prospective cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 598-607.	1.9	16
52	Longitudinal Trajectory of Fatigue in Patients With Inflammatory Bowel Disease: A Prospective Study. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1740-1746.	0.9	12
53	Women's Willingness to Accept Risks of Medication for Inflammatory Bowel Disease During Pregnancy. <i>Patient</i> , 2021, , .	1.1	0
54	Frailty in Patients With Inflammatory Bowel Disease. <i>Gastroenterology and Hepatology</i> , 2021, 17, 263-268.	0.2	0

#	ARTICLE	IF	CITATIONS
55	Discordance Between Patient-Reported Outcomes and Mucosal Inflammation in Patients With Mild to Moderate Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1760-1768.e1.	2.4	22
56	Ulcerative Colitis and Crohn's Disease Have Similar Burden and Goals for Treatment. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 14-23.	2.4	108
57	Interval Colorectal Cancer in Inflammatory Bowel Disease: The Role of Guideline Adherence. <i>Digestive Diseases and Sciences</i> , 2020, 65, 111-118.	1.1	20
58	Gastrointestinal Diseases. , 2020, , 16-26.		3
59	Association Between Vulvovaginal Discomfort and Activity of Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 604-611.e1.	2.4	14
60	Longitudinal Trajectory of Fatigue With Initiation of Biologic Therapy in Inflammatory Bowel Diseases: A Prospective Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 309-315.	0.6	31
61	Acute Venous Thromboembolism Risk Highest Within 60 Days After Discharge From the Hospital in Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1133-1141.e3.	2.4	43
62	Complete histologic normalisation is associated with reduced risk of relapse among patients with ulcerative colitis in complete endoscopic remission. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 347-355.	1.9	50
63	Use of Narrative Concepts in Electronic Health Records to Validate Associations Between Genetic Factors and Response to Treatment of Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1890-1892.	2.4	2
64	Estimating average treatment effects with a double-index propensity score. <i>Biometrics</i> , 2020, 76, 767-777.	0.8	8
65	Incidence and Predictors of Flares in the Postpartum Year Among Women With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1926-1932.	0.9	23
66	Hormone Therapy for Cancer Is a Risk Factor for Relapse of Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 872-880.e1.	2.4	16
67	Assessment of Benefit of Advanced Inflammatory Bowel Disease Training: Challenges and Solutions. <i>Crohn's &amp; Colitis 360</i> , 2020, 2, otaa019.	0.5	1
68	Disease and Treatment Patterns Among Patients With Pouch-related Conditions in a Cohort of Large Tertiary Care Inflammatory Bowel Disease Centers in the United States. <i>Crohn's &amp; Colitis 360</i> , 2020, 2, otaa039.	0.5	8
69	Multi-omic Profiling in Patients With Quiescent Inflammatory Bowel Disease Identifies Biomarkers Predicting Relapse. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1524-1532.	0.9	36
70	Changing Global Epidemiology of Inflammatory Bowel Diseases: Sustaining Health Care Delivery Into the 21st Century. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1252-1260.	2.4	153
71	Reply. <i>Gastroenterology</i> , 2020, 159, 1993-1994.	0.6	0
72	Dietary Inflammatory Potential and Risk of Crohn's Disease and Ulcerative Colitis. <i>Gastroenterology</i> , 2020, 159, 873-883.e1.	0.6	96

#	ARTICLE	IF	CITATIONS
73	Sa1836 FRAILITY AS A RISK FACTOR FOR HOSPITAL READMISSION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A NATIONWIDE STUDY. <i>Gastroenterology</i> , 2020, 158, S-445-S-446.	0.6	1
74	Clinical Research and Trialsâ€”A â€œNonessentialâ€”Victim of the COVID-19 Pandemic?. <i>American Journal of Gastroenterology</i> , 2020, 115, 946-947.	0.2	4
75	Case 8-2020: An 89-Year-Old Man with Recurrent Abdominal Pain and Bloody Stools. <i>New England Journal of Medicine</i> , 2020, 382, 1042-1052.	13.9	1
76	Risk of Tuberculosis in Patients With Inflammatory Bowel Disease on Infliximab or Adalimumab Is Dependent on the Local Disease Burden of Tuberculosis: A Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2020, 115, 340-349.	0.2	37
77	Frailty is independently associated with mortality in 11,001 patients with inflammatory bowel diseases. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 311-318.	1.9	40
78	Assessment of Body Weight Changes in Patients with Inflammatory Bowel Diseases Initiating Biologic Therapy: A Prospective Cohort Study. <i>Digestive Diseases and Sciences</i> , 2020, 65, 3672-3678.	1.1	7
79	Pretreatment Frailty Is Independently Associated With Increased Risk of Infections After Immunosuppression in Patients With Inflammatory Bowel Diseases. <i>Gastroenterology</i> , 2020, 158, 2104-2111.e2.	0.6	81
80	Editorial: histologic normalisation in ulcerative colitis. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 401-401.	1.9	1
81	Management of Inflammatory Bowel Diseases: Clinical Perspectives. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1249-1251.	2.4	1
82	Dietary Guidance From the International Organization for the Study of Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1381-1392.	2.4	161
83	Assessing National Trends and Disparities in Ambulatory, Emergency Department, and Inpatient Visits for Inflammatory Bowel Disease in the United States (2005â€”2016). <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2500-2509.e1.	2.4	27
84	The Doctor Will Call You Now! Telemedicine in the Midst of a Pandemic. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1688-1690.	2.4	18
85	Impact of Diet on Risk of IBD. <i>Crohn's &amp; Colitis 360</i> , 2020, 2, .	0.5	7
86	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1919.	2.4	0
87	Intra- and Inter-cellular Rewiring of the Human Colon during Ulcerative Colitis. <i>Cell</i> , 2019, 178, 714-730.e22.	13.5	806
88	The Role of the Radiologist in Determining Disease Severity in Inflammatory Bowel Diseases. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2019, 29, 447-470.	0.6	34
89	Analysis of Safety, Medical Resource Utilization, and Treatment Costs by Drug Class for Management of Inflammatory Bowel Disease in the United States Based on Insurance Claims Data. <i>Advances in Therapy</i> , 2019, 36, 3079-3095.	1.3	23
90	Tofacitinib: A Jak of All Trades. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1438-1440.	2.4	6

#	ARTICLE	IF	CITATIONS
91	The Crohn's disease polymorphism, ATG16L1 T300A, alters the gut microbiota and enhances the local Th1/Th17 response. <i>ELife</i> , 2019, 8, .	2.8	84
92	Immunologic Alterations Associated With Oral Delivery of Anti-CD3 (OKT3) Monoclonal Antibodies in Patients With Moderate-to-Severe Ulcerative Colitis. <i>Crohn's &amp; Colitis</i> 360, 2019, 1, otz009.	0.5	13
93	Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. <i>Nature</i> , 2019, 569, 655-662.	13.7	1,638
94	Low-dose Methotrexate has Similar Outcomes to High-dose Methotrexate in Combination with Anti-TNF Therapy in Inflammatory Bowel Diseases. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 990-995.	0.6	6
95	Safety of Biologic Therapy in Older Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1736-1743.e4.	2.4	76
96	Association of Genetic Variants in <i>NUDT15</i> With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 773.	3.8	129
97	CT-Visualized Colonic Mural Stratification Independently Predicts the Need for Medical or Surgical Rescue Therapy in Hospitalized Ulcerative Colitis Patients. <i>Digestive Diseases and Sciences</i> , 2019, 64, 2265-2272.	1.1	3
98	Comparative safety and effectiveness of tumor necrosis factor $\pm$ antagonists and vedolizumab in elderly IBD patients: a multicentre study. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 873-879.	1.9	76
99	High-throughput phenotyping with electronic medical record data using a common semi-supervised approach (PheCAP). <i>Nature Protocols</i> , 2019, 14, 3426-3444.	5.5	94
100	ACG Clinical Guideline: Ulcerative Colitis in Adults. <i>American Journal of Gastroenterology</i> , 2019, 114, 384-413.	0.2	933
101	Effect of Accelerated Infliximab Induction on Short- and Long-term Outcomes of Acute Severe Ulcerative Colitis: A Retrospective Multicenter Study and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 502-509.e1.	2.4	69
102	Patient age determines adherence to preventive care measures among patients with ulcerative colitis. <i>Digestive and Liver Disease</i> , 2019, 51, 178-179.	0.4	0
103	Comparable perioperative outcomes, long-term outcomes, and quality of life in a retrospective analysis of ulcerative colitis patients following 2-stage versus 3-stage proctocolectomy with ileal pouch-anal anastomosis. <i>International Journal of Colorectal Disease</i> , 2019, 34, 491-499.	1.0	28
104	Cancer risk in microscopic colitis: a retrospective cohort study. <i>BMC Gastroenterology</i> , 2019, 19, 1.	0.8	48
105	Fatigue in IBD: epidemiology, pathophysiology and management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 247-259.	8.2	137
106	The Gut Microbiome and Digestive Health – A New Frontier. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 215-217.	2.4	7
107	Paternal Disease Activity Is Associated With Difficulty in Conception Among Men With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 203-204.	2.4	9
108	Influence of Environmental Factors in the Development and Outcomes of Inflammatory Bowel Disease. <i>Gastroenterology and Hepatology</i> , 2019, 15, 72-82.	0.2	15

#	ARTICLE	IF	CITATIONS
109	Smoking is Associated with an Increased Risk of Microscopic Colitis: Results From Two Large Prospective Cohort Studies of US Women. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 559-567.	0.6	31
110	Loss of Response to Anti-Tumor Necrosis Factor Alpha Therapy in Crohn's Disease Is Not Associated with Emergence of Novel Inflammatory Pathways. <i>Digestive Diseases and Sciences</i> , 2018, 63, 738-745.	1.1	16
111	Enabling phenotypic big data with PheNorm. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2018, 25, 54-60.	2.2	82
112	Dynamics of metatranscription in the inflammatory bowel disease gut microbiome. <i>Nature Microbiology</i> , 2018, 3, 337-346.	5.9	408
113	Differences in Clinical Course, Genetics, and the Microbiome Between Familial and Sporadic Inflammatory Bowel Diseases. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 525-531.	0.6	22
114	Genetic Markers Predict Primary Nonresponse and Durable Response to Anti-Tumor Necrosis Factor Therapy in Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1840-1848.	0.9	34
115	Effect of oral tobacco use and smoking on outcomes of Crohn's disease in India. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 134-140.	1.4	13
116	Ethnicity Influences Phenotype and Outcomes in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis of Population-based Studies. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 190-197.e11.	2.4	84
117	Environmental triggers in IBD: a review of progress and evidence. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 39-49.	8.2	573
118	Use of Biologic Therapy by Pregnant Women With Inflammatory Bowel Disease Does Not Affect Infant Response to Vaccines. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 99-105.	2.4	97
119	A Case Study of the Incremental Utility for Disease Identification of Natural Language Processing in Electronic Medical Records. <i>Pharmaceutical Medicine</i> , 2018, 32, 31-37.	1.0	7
120	Weekend Effect in Patients With Upper Gastrointestinal Hemorrhage: A Systematic Review and Meta-analysis. <i>American Journal of Gastroenterology</i> , 2018, 113, 13-21.	0.2	31
121	Identification of Menopausal and Reproductive Risk Factors for Microscopic Colitis: Results From the Nurses' Health Study. <i>Gastroenterology</i> , 2018, 155, 1764-1775.e2.	0.6	24
122	Bugs and drugs: Predicting response to therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 27-27.	1.4	0
123	The Effect of Early-Life Environmental Exposures on Disease Phenotype and Clinical Course of Crohn's Disease in Children. <i>American Journal of Gastroenterology</i> , 2018, 113, 1524-1529.	0.2	33
124	Making sense of clinical predictors. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 7-8.	1.4	0
125	Debate session: So what causes inflammatory bowel disease? It's all in the environment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 24-24.	1.4	5
126	The role of diet in the aetiopathogenesis of inflammatory bowel disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 525-535.	8.2	178



#	ARTICLE	IF	CITATIONS
127	Lack of Difference in Treatment Patterns and Clinical Outcomes Between Black and White Patients With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2634-2640.	0.9	20
128	<i>IRGM</i> Gene Variants Modify the Relationship Between Visceral Adipose Tissue and NAFLD in Patients With Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2247-2257.	0.9	19
129	Does Obesity Influence the Risk of <i>Clostridium difficile</i> Infection Among Patients with Ulcerative Colitis?. <i>Digestive Diseases and Sciences</i> , 2018, 63, 2445-2450.	1.1	12
130	The Association Between Arthralgia and Vedolizumab Using Natural Language Processing. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2242-2246.	0.9	23
131	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1177.	2.4	0
132	Development of a Sexual Dysfunction Scale for Women With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2350-2359.	0.9	23
133	Long-Term Outcomes of Immunosuppression-Naïve Steroid Responders Following Hospitalization for Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , 2018, 63, 2740-2746.	1.1	10
134	Reply to "Comment on Sarcopenia is a Novel Predictor of the Need for Rescue Therapy in Hospitalized Ulcerative Colitis Patients". <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1256-1256.	0.6	23
135	Sarcopenia is a Novel Predictor of the Need for Rescue Therapy in Hospitalized Ulcerative Colitis Patients. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1036-1041.	0.6	23
136	Predictability and persistence of prebiotic dietary supplementation in a healthy human cohort. <i>Scientific Reports</i> , 2018, 8, 12699.	1.6	37
137	A low-cost paper-based synthetic biology platform for analyzing gut microbiota and host biomarkers. <i>Nature Communications</i> , 2018, 9, 3347.	5.8	192
138	The impact of coexisting immune-mediated diseases on phenotype and outcomes in inflammatory bowel diseases. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 814-823.	1.9	31
139	Risk of colorectal cancer in Asian patients with ulcerative colitis: a systematic review and meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 269-276.	3.7	139
140	Genetic risk factors for serious infections in inflammatory bowel diseases. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 570-576.	0.6	6
141	Modifiable Environmental Factors in Inflammatory Bowel Disease. <i>Current Gastroenterology Reports</i> , 2017, 19, 21.	1.1	27
142	Management of Inflammatory Bowel Disease in the Elderly Patient. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 882-893.	0.9	75
143	Inflammatory Bowel Disease is Similar in Patients with Older Onset and Younger Onset. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 1187-1194.	0.9	16
144	Gut Microbiome Function Predicts Response to Anti-integrin Biologic Therapy in Inflammatory Bowel Diseases. <i>Cell Host and Microbe</i> , 2017, 21, 603-610.e3.	5.1	306

#	ARTICLE	IF	CITATIONS
145	The benefit of combination therapy depends on disease phenotype and duration in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 162-168.	1.9	15
146	Dietary Iron and Heme Iron Consumption, Genetic Susceptibility, and Risk of Crohn's Disease and Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 1088-1095.	0.9	29
147	Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1291-1302.	1.9	230
148	Editorial: co-existing immune-mediated disease in inflammatory bowel diseases – a new disease severity indicator? Author's reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1168-1168.	1.9	0
149	Predictors of Clinical Response and Remission at 1 Year Among a Multicenter Cohort of Patients with Inflammatory Bowel Disease Treated with Vedolizumab. <i>Digestive Diseases and Sciences</i> , 2017, 62, 1590-1596.	1.1	56
150	A Comprehensive Study of Costs Associated With Recurrent <i>Clostridium difficile</i> Infection. <i>Infection Control and Hospital Epidemiology</i> , 2017, 38, 196-202.	1.0	48
151	Filgotinib for Crohn's disease – expanding treatment options. <i>Lancet, The</i> , 2017, 389, 228-229.	6.3	4
152	Genetic Polymorphisms in Fatty Acid Metabolism Modify the Association Between Dietary n3. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 1898-1904.	0.9	30
153	Letter: enteral nutrition therapy for the induction of remission in paediatric Crohn's disease – Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 1026-1027.	1.9	0
154	Systematic review with meta-analysis: breastfeeding and the risk of Crohn's disease and ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 780-789.	1.9	163
155	Systematic review with meta-analysis: enteral nutrition therapy for the induction of remission in paediatric Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 645-656.	1.9	121
156	Letter: reproducible evidence shows that exclusive enteral nutrition significantly reduces faecal calprotectin concentrations in children with active Crohn's disease – Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 1121-1121.	1.9	0
157	Vedolizumab Therapy Is Associated with an Improvement in Sleep Quality and Mood in Inflammatory Bowel Diseases. <i>Digestive Diseases and Sciences</i> , 2017, 62, 197-206.	1.1	45
158	Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn's disease and ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 3-13.	1.9	190
159	Surrogate-assisted feature extraction for high-throughput phenotyping. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2017, 24, e143-e149.	2.2	68
160	Asians Have More Perianal Crohn Disease and Ocular Manifestations Compared with White Americans. <i>Inflammatory Intestinal Diseases</i> , 2017, 2, 147-153.	0.8	21
161	Pivot to Asia: inflammatory bowel disease burden. <i>Intestinal Research</i> , 2017, 15, 138.	1.0	80
162	The emergence of <i>Clostridium difficile</i> infection in Asia: A systematic review and meta-analysis of incidence and impact. <i>PLoS ONE</i> , 2017, 12, e0176797.	1.1	77

#	ARTICLE	IF	CITATIONS
163	Identification and Characterization of a Novel Association between Dietary Potassium and Risk of Crohn's Disease and Ulcerative Colitis. <i>Frontiers in Immunology</i> , 2016, 7, 554.	2.2	42
164	<scp>HBV</scp>/<scp>HIV</scp> coinfection is associated with poorer outcomes in hospitalized patients with <scp>HBV</scp> or <scp>HIV</scp>. <i>Journal of Viral Hepatitis</i> , 2016, 23, 820-829.	1.0	36
165	<i>Clostridium difficile</i> associated risk of death score (<scp>CARDS</scp>): a novel severity score to predict mortality among hospitalised patients with <i>C. difficile</i> infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 725-733.	1.9	65
166	Identification of Nonresponse to Treatment Using Narrative Data in an Electronic Health Record Inflammatory Bowel Disease Cohort. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 151-158.	0.9	16
167	Environmental Hygiene and Risk of Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 2191-2199.	0.9	63
168	Cancer Recurrence Following Immune-Suppressive Therapies in Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis. <i>Gastroenterology</i> , 2016, 151, 97-109.e4.	0.6	120
169	Clinical Activity and Quality of Life Indices Are Valid Across Ulcerative Colitis But Not Crohn's Disease Phenotypes. <i>Digestive Diseases and Sciences</i> , 2016, 61, 2627-2635.	1.1	15
170	P-014 Circulating C-Reactive Protein and Interleukin-6 and Risk of Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2016, 22, S13-S14.	0.9	0
171	Racial Disparities in Inhospital Outcomes for Hepatocellular Carcinoma in the United States. <i>Mayo Clinic Proceedings</i> , 2016, 91, 1173-1182.	1.4	15
172	A Pleiotropic Missense Variant in SLC39A8 Is Associated With Crohn's Disease and Human Gut Microbiome Composition. <i>Gastroenterology</i> , 2016, 151, 724-732.	0.6	109
173	Adjuvant use of antibiotics with corticosteroids in inflammatory bowel disease exacerbations requiring hospitalisation: a retrospective cohort study and meta-analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 52-60.	1.9	22
174	Infliximab or ciclosporin for acute severe ulcerative colitis?. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 2-3.	3.7	2
175	A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis. <i>Nature Communications</i> , 2016, 7, 12342.	5.8	50
176	Comparative Effectiveness of Infliximab and Adalimumab in Crohn's Disease and Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 880-885.	0.9	44
177	Toward reducing bias in clinical trials: central readers for endoscopic endpoints. <i>Gastrointestinal Endoscopy</i> , 2016, 83, 198-200.	0.5	4
178	Metagenomic Characterization of Microbial Communities In Situ Within the Deeper Layers of the Ileum in Crohn's Disease. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2016, 2, 563-566.e5.	2.3	23
179	Discontinuity of care for mothers with chronic hepatitis B diagnosed during pregnancy. <i>Journal of Viral Hepatitis</i> , 2016, 23, 561-568.	1.0	9
180	Chromoendoscopy Is Better: So Why Am I Not (yet) Using it for Routine Inflammatory Bowel Disease Surveillance?. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 720-722.	2.4	10

#	ARTICLE	IF	CITATIONS
181	Association Between Circulating Levels of C-Reactive Protein and Interleukin-6 and Risk of Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 818-824.e6.	2.4	61
182	Statin Use Is Associated With Reduced Risk of Colorectal Cancer in Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 973-979.	2.4	56
183	Systematic Review and Meta-analysis: Phenotype and Clinical Outcomes of Older-onset Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 1224-1236.	0.6	122
184	Computer-assisted expert case definition in electronic health records. <i>International Journal of Medical Informatics</i> , 2016, 86, 62-70.	1.6	30
185	Diagnostic and Therapeutic Yield of Endoscopy in Patients with Elevated INR and Gastrointestinal Bleeding. <i>American Journal of Medicine</i> , 2016, 129, 628-634.	0.6	10
186	Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease and Previous Cancer Exposed to Immunosuppressive and Anti-Tumor Necrosis Factor Agents. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 58-64.	2.4	93
187	Editorial: diabetes and the risk of infections with immunomodulator therapy in inflammatory bowel diseases – author's reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 120-120.	1.9	0
188	High School Diet and Risk of Crohn's Disease and Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1.	0.9	80
189	New onset idiosyncratic liver enzyme elevations with biological therapy in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 972-979.	1.9	52
190	Development of phenotype algorithms using electronic medical records and incorporating natural language processing. <i>BMJ, The</i> , 2015, 350, h1885-h1885.	3.0	226
191	Body Mass Index, Genetic Susceptibility, and Risk of Complications Among Individuals with Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1.	0.9	45
192	Common Genetic Variants Influence Circulating Vitamin D Levels in Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 2507-2514.	0.9	30
193	Zinc intake and risk of Crohn's disease and ulcerative colitis: a prospective cohort study. <i>International Journal of Epidemiology</i> , 2015, 44, 1995-2005.	0.9	83
194	The Toronto Consensus Guidelines for Nonhospitalized Ulcerative Colitis: A Welcome Update but Not the End of the Story. <i>Gastroenterology</i> , 2015, 148, 877-880.	0.6	1
195	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1703-1704.	2.4	0
196	Colonoscopy Is Associated With a Reduced Risk for Colon Cancer and Mortality in Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 322-329.e1.	2.4	107
197	Surgery for Crohn's disease: look harder, act faster. <i>Lancet, The</i> , 2015, 385, 1370-1371.	6.3	9
198	Epidemiology and risk factors for IBD. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015, 12, 205-217.	8.2	1,202

#	ARTICLE	IF	CITATIONS
199	High C-Reactive Protein Is Associated with Poor Sleep Quality Independent of Nocturnal Symptoms in Patients with Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2015, 60, 2136-2143.	1.1	45
200	Mode of Childbirth and Long-Term Outcomes in Women with Inflammatory Bowel Diseases. <i>Digestive Diseases and Sciences</i> , 2015, 60, 471-477.	1.1	27
201	Patient Electronic Health Records as a Means to Approach Genetic Research in Gastroenterology. <i>Gastroenterology</i> , 2015, 149, 1134-1137.	0.6	3
202	Variation in Treatment of Patients With Inflammatory Bowel Diseases at Major Referral Centers in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1197-1200.	2.4	47
203	Measures of Obesity and Risk of Crohn's Disease and Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 361-368.	0.9	123
204	Diabetes and the risk of infections with immunomodulator therapy in inflammatory bowel diseases. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 1141-1148.	1.9	38
205	The Holy Grail, or Only Half Way There?. <i>Gastroenterology</i> , 2015, 148, 8-10.	0.6	2
206	Environmental Risk Factors for Inflammatory Bowel Diseases: A Review. <i>Digestive Diseases and Sciences</i> , 2015, 60, 290-298.	1.1	136
207	Methods to Develop an Electronic Medical Record Phenotype Algorithm to Compare the Risk of Coronary Artery Disease across 3 Chronic Disease Cohorts. <i>PLoS ONE</i> , 2015, 10, e0136651.	1.1	82
208	Early life environment and natural history of inflammatory bowel diseases. <i>BMC Gastroenterology</i> , 2014, 14, 216.	0.8	34
209	Pretreatment 25-hydroxyvitamin D Levels and Durability of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Diseases. <i>Journal of Parenteral and Enteral Nutrition</i> , 2014, 38, 385-391.	1.3	98
210	Evaluation of matched control algorithms in EHR-based phenotyping studies: A case study of inflammatory bowel disease comorbidities. <i>Journal of Biomedical Informatics</i> , 2014, 52, 105-111.	2.5	21
211	Higher plasma vitamin D is associated with reduced risk of <i>Clostridium difficile</i> infection in patients with inflammatory bowel diseases. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 1136-1142.	1.9	56
212	Vitamin D deficiency is associated with community-acquired <i>clostridium difficile</i> infection: a case-control study. <i>BMC Infectious Diseases</i> , 2014, 14, 661.	1.3	15
213	Genetic Polymorphisms in Metabolizing Enzymes Modifying the Association Between Smoking and Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 783-789.	0.9	34
214	Thromboprophylaxis Is Associated With Reduced Post-hospitalization Venous Thromboembolic Events in Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1905-1910.	2.4	61
215	Mortality and extraintestinal cancers in patients with primary sclerosing cholangitis and inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 956-963.	0.6	49
216	Cost-effectiveness of Competing Strategies for Management of Recurrent <i>Clostridium difficile</i> Infection: A Decision Analysis. <i>Clinical Infectious Diseases</i> , 2014, 58, 1507-1514.	2.9	128

#	ARTICLE	IF	CITATIONS
217	Association Between Reduced Plasma 25-Hydroxy Vitamin D and Increased Risk of Cancer in Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 821-827.	2.4	101
218	Differential Effect of Genetic Burden on Disease Phenotypes in Crohn's Disease and Ulcerative Colitis: Analysis of a North American Cohort. <i>American Journal of Gastroenterology</i> , 2014, 109, 395-400.	0.2	77
219	Long-term intake of dietary fat and risk of ulcerative colitis and Crohn's disease. <i>Gut</i> , 2014, 63, 776-784.	6.1	386
220	Review article: vitamin D and inflammatory bowel diseases. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 125-136.	1.9	181
221	Sleep Duration Affects Risk for Ulcerative Colitis: A Prospective Cohort Study. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1879-1886.	2.4	76
222	Serum Inflammatory Markers and Risk of Colorectal Cancer in Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1342-1348.e1.	2.4	38
223	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1577-1578.	2.4	0
224	SMAD3 gene variant is a risk factor for recurrent surgery in patients with Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 845-851.	0.6	46
225	Can Mucosal Healing Be a Cost-effective Endpoint for Biologic Therapy in Crohn's Disease? A Decision Analysis. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 37-44.	0.9	43
226	Older Age Is Associated with Higher Rate of Discontinuation of Anti-TNF Therapy in Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 309-315.	0.9	127
227	Treatment of Intra-Abdominal Abscesses in Crohn's Disease: A Nationwide Analysis of Patterns and Outcomes of Care. <i>Digestive Diseases and Sciences</i> , 2013, 58, 2013-2018.	1.1	23
228	Interobserver Agreement for the Detection of Barrett's Esophagus with Optical Frequency Domain Imaging. <i>Digestive Diseases and Sciences</i> , 2013, 58, 2261-2265.	1.1	43
229	Dyssynergic Defecation: A Treatable Cause of Persistent Symptoms When Inflammatory Bowel Disease Is in Remission. <i>Digestive Diseases and Sciences</i> , 2013, 58, 3600-3605.	1.1	32
230	A Prospective Study of Long-term Intake of Dietary Fiber and Risk of Crohn's Disease and Ulcerative Colitis. <i>Gastroenterology</i> , 2013, 145, 970-977.	0.6	494
231	Personalizing therapy for inflammatory bowel diseases. <i>Expert Review of Gastroenterology and Hepatology</i> , 2013, 7, 549-558.	1.4	10
232	Sleep Disturbance and Risk of Active Disease in Patients With Crohn's Disease and Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 965-971.	2.4	192
233	Association Between Depressive Symptoms and Incidence of Crohn's Disease and Ulcerative Colitis: Results From the Nurses' Health Study. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 57-62.	2.4	123
234	Antibiotic exposure is associated with development of inflammatory bowel disease. <i>Journal of Pediatrics</i> , 2013, 162, 1077.	0.9	1

#	ARTICLE	IF	CITATIONS
235	Psychiatric co-morbidity is associated with increased risk of surgery in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 445-454.	1.9	101
236	Impact of Coexistent Celiac Disease on Phenotype and Natural History of Inflammatory Bowel Diseases. <i>American Journal of Gastroenterology</i> , 2013, 108, 1123-1129.	0.2	48
237	Guidelines for Diagnosis, Treatment, and Prevention of <i>Clostridium difficile</i> Infections. <i>American Journal of Gastroenterology</i> , 2013, 108, 478-498.	0.2	1,413
238	Similar Risk of Depression and Anxiety Following Surgery or Hospitalization for Crohn's Disease and Ulcerative Colitis. <i>American Journal of Gastroenterology</i> , 2013, 108, 594-601.	0.2	72
239	Environmental Triggers for Inflammatory Bowel Disease. <i>Current Gastroenterology Reports</i> , 2013, 15, 302.	1.1	91
240	Infection-related hospitalizations are associated with increased mortality in patients with inflammatory bowel diseases. <i>Journal of Crohn's and Colitis</i> , 2013, 7, 107-112.	0.6	155
241	Improving Case Definition of Crohn's Disease and Ulcerative Colitis in Electronic Medical Records Using Natural Language Processing. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 1411-1420.	0.9	142
242	Genetic risk factors for <i>Clostridium difficile</i> infection in ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 522-530.	1.9	49
243	Weekend hospitalisations and post-operative complications following urgent surgery for ulcerative colitis and Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 895-904.	1.9	35
244	Normalization of Plasma 25-Hydroxy Vitamin D Is Associated with Reduced Risk of Surgery in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 1.	0.9	168
245	Early Life Factors and Risk of Inflammatory Bowel Disease in Adulthood. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 542-547.	0.9	50
246	P-056 Aryl Hydrocarbon Receptor Expression: A Comparison Between Patients with IBD and Healthy Controls, and Association with Serum Fatty Acids. <i>Inflammatory Bowel Diseases</i> , 2013, 19, S49-S50.	0.9	0
247	How Does Genotype Influence Disease Phenotype in Inflammatory Bowel Disease?. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 1.	0.9	14
248	Aspirin, Nonsteroidal Anti-inflammatory Drug Use, and Risk for Crohn Disease and Ulcerative Colitis. <i>Annals of Internal Medicine</i> , 2012, 156, 350.	2.0	223
249	Impact of pregnancy on health-related quality of life of patients with inflammatory bowel disease. <i>Journal of Digestive Diseases</i> , 2012, 13, 472-477.	0.7	8
250	Geographical variation and incidence of inflammatory bowel disease among US women. <i>Gut</i> , 2012, 61, 1686-1692.	6.1	187
251	Detecting and Treating <i>Clostridium Difficile</i> Infections in Patients with Inflammatory Bowel Disease. <i>Gastroenterology Clinics of North America</i> , 2012, 41, 339-353.	1.0	30
252	Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. <i>Nature</i> , 2012, 491, 119-124.	13.7	4,038

#	ARTICLE	IF	CITATIONS
253	Reply to Dr. McNabb-Baltar's letter. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 868.	0.6	0
254	Predictors of severe outcomes associated with <i>Clostridium difficile</i> infection in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 789-795.	1.9	79
255	Long-term outcome of a third anti-TNF monoclonal antibody after the failure of two prior anti-TNFs in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 459-466.	1.9	48
256	Certolizumab Pegol Compared to Natalizumab in Patients with Moderate to Severe Crohn's Disease: Results of a Decision Analysis. <i>Digestive Diseases and Sciences</i> , 2012, 57, 472-480.	1.1	18
257	Strategies for the Prevention of Postoperative Recurrence in Crohn's Disease: Results of a Decision Analysis. <i>American Journal of Gastroenterology</i> , 2011, 106, 2009-2017.	0.2	44
258	<i>Clostridium difficile</i> infection: epidemiology, risk factors and management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2011, 8, 17-26.	8.2	313
259	Geographic variation and the incidence of inflammatory bowel disease among U.S. women. <i>Inflammatory Bowel Diseases</i> , 2011, 17, S15.	0.9	0
260	Fracture-Associated Hospitalizations in Patients with Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2011, 56, 176-182.	1.1	20
261	Deep Vein Thrombosis and Pulmonary Embolism in Hospitalized Patients with Cirrhosis: A Nationwide Analysis. <i>Digestive Diseases and Sciences</i> , 2011, 56, 2152-2159.	1.1	71
262	A Nationwide Analysis of Changes in Severity and Outcomes of Inflammatory Bowel Disease Hospitalizations. <i>Journal of Gastrointestinal Surgery</i> , 2011, 15, 267-276.	0.9	62
263	Physician density and hospitalization for inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 633-638.	0.9	7
264	Ambient air pollution correlates with hospitalizations for inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 1138-1145.	0.9	127
265	Temporal trends in disease outcomes related to <i>Clostridium difficile</i> infection in patients with inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 976-983.	0.9	130
266	Impact of Autonomic Dysfunction on Inflammatory Bowel Disease. <i>Journal of Clinical Gastroenterology</i> , 2010, 44, 272-279.	1.1	25
267	Laparoscopic Resection for Inflammatory Bowel Disease: Outcomes from a Nationwide Sample. <i>Journal of Gastrointestinal Surgery</i> , 2010, 14, 58-65.	0.9	21
268	Higher Physician Density is Associated with Lower Incidence of Late-stage Colorectal Cancer. <i>Journal of General Internal Medicine</i> , 2010, 25, 1164-1171.	1.3	60
269	Does primary sclerosing cholangitis impact quality of life in patients with inflammatory bowel disease?. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 494-500.	0.9	24
270	<i>Clostridium difficile</i> and inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 1445-1446.	0.9	4



#	ARTICLE	IF	CITATIONS
271	Simple score to identify colectomy risk in ulcerative colitis hospitalizations. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 1532-1540.	0.9	37
272	Hepatitis C/HIV co-infection is associated with higher mortality in hospitalized patients with Hepatitis C or HIV. <i>Journal of Viral Hepatitis</i> , 2010, 17, 720-729.	1.0	19
273	Trends in Ambulatory and Emergency Room Visits for Inflammatory Bowel Diseases in the United States: 1994-2005. <i>American Journal of Gastroenterology</i> , 2010, 105, 363-370.	0.2	48
274	A Novel Risk Score to Stratify Severity of Crohn's Disease Hospitalizations. <i>American Journal of Gastroenterology</i> , 2010, 105, 1799-1807.	0.2	55
275	Length of Office Visits for Gastrointestinal Disease: Impact of Physician Specialty. <i>American Journal of Gastroenterology</i> , 2010, 105, 1719-1725.	0.2	6
276	Improved Efficacy of Biological Maintenance Therapy in "Early" Compared With "Late" Crohn's Disease: Strike While the Iron Is Hot With Anti-TNF Agents?. <i>American Journal of Gastroenterology</i> , 2010, 105, 1583-1585.	0.2	9
277	Clostridium Difficile and Inflammatory Bowel Disease. <i>Medical Clinics of North America</i> , 2010, 94, 135-153.	1.1	40
278	Impact of Clostridium difficile on inflammatory bowel disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2010, 4, 589-600.	1.4	31
279	Treatment of Ulcerative Colitis in the Elderly. <i>Digestive Diseases</i> , 2009, 27, 327-334.	0.8	34
280	Inflammatory bowel disease in the elderly is associated with worse outcomes: A national study of hospitalizations. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 182-189.	0.9	175
281	History of medical hospitalization predicts future need for colectomy in patients with ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 176-181.	0.9	67
282	Higher hospital volume predicts endoscopy but not the in-hospital mortality rate in patients with acute variceal hemorrhage. <i>Gastrointestinal Endoscopy</i> , 2009, 69, 221-229.	0.5	9
283	Higher hospital volume is associated with lower mortality in acute nonvariceal upper-GI hemorrhage. <i>Gastrointestinal Endoscopy</i> , 2009, 70, 422-432.	0.5	24
284	Outcomes of Weekend Admissions for Upper Gastrointestinal Hemorrhage: A Nationwide Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 296-302.e1.	2.4	153
285	Clostridium Difficile and Inflammatory Bowel Disease. <i>Gastroenterology Clinics of North America</i> , 2009, 38, 711-728.	1.0	59
286	Effect of hospital volume and teaching status on outcomes of acute liver failure. <i>Liver Transplantation</i> , 2008, 14, 1347-1356.	1.3	28
287	Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. <i>Gut</i> , 2008, 57, 205-210.	6.1	364
288	Does It Matter Where You Are Hospitalized for Inflammatory Bowel Disease? A Nationwide Analysis of Hospital Volume. <i>American Journal of Gastroenterology</i> , 2008, 103, 2789-2798.	0.2	115

#	ARTICLE	IF	CITATIONS
289	Permanent Work Disability in Crohn's Disease. American Journal of Gastroenterology, 2008, 103, 154-161.	0.2	90
290	Racial Differences in Liver Transplantation Outcomes in the MELD Era. American Journal of Gastroenterology, 2008, 103, 901-910.	0.2	72
291	Severe Pulmonary Toxicity After Azathioprine/6-Mercaptopurine Initiation for the Treatment of Inflammatory Bowel Disease. Journal of Clinical Gastroenterology, 2007, 41, 682-688.	1.1	55
292	Disparities in Colon Cancer Screening in the Medicare Population. Archives of Internal Medicine, 2007, 167, 258.	4.3	117
293	Caroli's disease: Identification and treatment strategy. Current Gastroenterology Reports, 2007, 9, 151-155.	1.1	48
294	Epidemiology of Primary and Secondary Liver Cancers. Seminars in Interventional Radiology, 2006, 23, 047-063.	0.3	150